X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

International collaboration finds 11 new Alzheimer’s genes to target for drug discovery

Yuvraj_pawp by Yuvraj_pawp
28th October 2013
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer’s disease genetics collaboration to date, which identified 11 new regions of the genome that contribute to late-onset Alzheimer’s disease, doubling the number of potential genetics-based therapeutic targets to investigate.

Published October 27 in Nature Genetics, the study gives a broader view of the genetic factors contributing to Alzheimer’s and expands the understanding of the disease to new areas, including the immune system, where a genetic overlap with other neurodegenerative diseases, including multiple sclerosis and Parkinson’s disease, was identified.

In 2011, the world’s four largest research consortia on the genetics of Alzheimer’s disease joined efforts to discover and map the genes that contribute to Alzheimer’s, forming the International Genomics of Alzheimer’s Project (IGAP). The team collected genetic information from 25,500 Alzheimer’s disease patients and 49,038 controls from 15 countries to perform this two-stage meta-analysis that resulted in the discovery of 11 new genes in addition to those already known, and the identification of 13 other genes, yet to be validated.

Margaret A. Pericak-Vance, Ph.D., the Dr. John T. Macdonald Foundation Professor of Human Genomics and Director of the John P. Hussman Institute for Human Genomics at the Miller School, and Lindsay A. Farrer, Ph.D., from Boston University, led the analysis teams for the American Alzheimer’s Disease Genetics Consortium, which includes nearly all of the nation’s researchers working on the genetics of Alzheimer’s, as well as many investigators and resources of the 29 federally funded Alzheimer’s Disease Centers.

Several of the genes the researchers identified confirmed known biological pathways of Alzheimer’s disease, including the role of the amyloid (SORL1, CASS4) and tau (CASS4, FERMT2) pathways. Newly discovered genes involved in the immune response and inflammation (HLA-DRB5/DRB1, INPP5D, MEF2C) reinforced a pathway implied by previous work (on CR1, TREM2). Additional genes related to cell migration (PTK2B), lipid transport and endocytosis (SORL1) also were confirmed, and new hypotheses emerged related to hippocampal synaptic function (MEF2C, PTK2B), the cytoskeleton and axonal transport (CELF1, NME8, CASS4), as well as myeloid and microglial cell functions (INPP5D).

One of the more significant new associations was found in the HLA-DRB5/DRB1 region, one of the most complex parts of the genome, which plays a role in the immune system and inflammatory response. It also has been associated with multiple sclerosis and Parkinson’s disease, suggesting that the diseases where abnormal proteins accumulate in the brain may have a common mechanism involved, and possibly a common drug target.

“The discovery of novel pathways is very encouraging considering the limited success of Alzheimer’s disease drugs tested so far,” Pericak-Vance said. “Our findings bring us closer toward identifying new drug targets for Alzheimer’s and other neurodegenerative diseases. We’ll continue to expand and analyze our data set with this incredible group so that we can better understand the genetic influences on this devastating disease, and find new medical and therapeutic interventions.”

Tags: America
Previous Post

AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability

Next Post

Stem cell breakthrough could set up future transplant therapies

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Stem cell breakthrough could set up future transplant therapies

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In